Bradley Hauser - 11 Aug 2025 Form 4 Insider Report for Autonomix Medical, Inc. (AMIX)

Reporting relationship: CEO and President
Issuer ticker: AMIX
Reported as of: 11 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Aug 2025, 21:19:59 UTC
Prior SEC filing: 20 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Trent Smith, Attorney-in-Fact for Brad Hauser

Key filing fact

Bradley Hauser filed Form 4 for Autonomix Medical, Inc. (AMIX) on 13 Aug 2025.

Key facts

This page summarizes Bradley Hauser's Form 4 filing for Autonomix Medical, Inc. (AMIX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Aug 2025, 21:19.

Change

Previous filing in this sequence was filed on 20 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001662139 Primary reporting owner

Hauser Bradley

Relationship: CEO and President
Address: C/O AUTONOMIX MEDICAL, INC., 21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS
Signature: /s/ Trent Smith, Attorney-in-Fact for Brad Hauser
Signature date: 13 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMIX transaction Derivative

Option (Right to buy)

Disposed to Issuer

Transaction value
Shares: -45,000
Change %: -100%
Price
Shares after: 0
Date: 11 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 45,000
Exercise price: $27.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received three months severance as consideration for the cancellation.